26 January 2017 in Immunologic Research
4 July 2013 in Biomedical Reports
Urticaria is one of the most frequent dermatoses and its prevalence in the general population is estimated to be ~20%, whereas a substantial percentage of the cases may be classified as chronic idiopathic urticaria (CIU). The inflammatory response presenting with spontaneous wheals exhibits pro‑inflammatory characteristics, involving a prominent role for lymphocytes with a mixed Th1/Th2 response in which interleukin (IL)‑2 and IL‑10 are prominently secreted by Th1 and Th2 cells, respectively. In CIU patients, it was demonstrated that IL‑10 production was elevated and IL‑2 reduced compared to controls. Therefore, inhibition of IL‑10 and promotion of IL‑2 production by the lymphocytes, indicating Th2 inhibition and Th1 promotion, may facilitate the treatment of CIU. Whether the polysaccharide nucleic acid fraction of bacillus calmette‑guérin (BCG‑PSN), which possesses multiple immunomodulatory properties, has that potential, remains to be elucidated. In this study, BCG‑PSN was used on lymphocytes isolated from CIU patients, with healthy donors used as controls. immunocytochemistry and ELISA were used to detect IL‑2 and IL‑10 production. It was demonstrated that the IL‑2 production by the lymphocytes in the CIU group was significantly lower compared to that in the healthy control group and it increased sequentially with the increase of the concentration of BCG‑PSN used. By contrast, the IL‑10 production by the lymphocytes in the CIU group was significantly higher compared to that in the healthy control group and decreased sequentially with the increase of the concentration of BCG‑PSN used. Thus, it may be concluded that the BCG‑PSN has the potential to promote IL‑2 and inhibit IL‑10 production in the lymphocytes of CIU patients, facilitating the treatment of CIU.
1 December 2019 in Immunologic Research
1 April 2014 in Biomedicine & Pharmacotherapy
1 November 2015 in Environmental Toxicology and Pharmacology
1 July 2025 in Cancer Biology & Therapy
Sufficient MHC-I expression on cancer cells is essential for the recognition and killing of cancer cells by immune effector cytotoxic T-lymphocyte (CTL). An important mechanism of cancer immune escape is loss or down-regulation of MHC-I. This is frequently associated with reduced expression of NOD-like receptor (NLR) caspase recruitment domain containing protein 5 (NLRC5), genetically and epigenetically. NLRC5, a regulator of MHC-I, has been identified as a potential target of miR-4319 due to its complementary binding site for miR-4319, according to prediction by TargetScan (http://www.targetscan.org/). Inhibition of miR-4319 by IFN-γ (known as MHC-I increasing agent) to upregulate NLRC5 with upregulation of MHC-I in MHC-I-deficient breast cancer cells, however, remains unclear. After treatment with IFN-γ, miR-4319 was detected with qRT-PCR; NLRC5 protein was detected with western-blot; and MHC-I mRNA and protein were detected with qRT-PCR and western-blot, respectively. It was found statistically that miR-4319 was lower and NLRC5 protein was higher in groups of 50 U/ml and 100 U/ml IFN-γ, and MHC-I mRNA and protein were higher in all groups of different concentrations of IFN-γ, except for HLA-A protein in 25 U/ml IFN-γ group, with dose dependent tendency, compared with the control group. IFN-γ inhibits miR-4319 and upregulates NLRC5, thereby enhancing expression of MHC-I in SKBR3 breast cancer cells, while limitations include the absence of functional rescue experiments and in vivo validation. Along with direct cytotoxicity on tumor cells, IFN-γ's immunomodulatory effect strengthens tumor immunogenicity, counteracts immune evasion mechanisms, and potentially improves the efficacy of cancer immunotherapy.